Amphastar Pharmaceuticals (AMPH) FY2020 results: revenue $350 million, up 8.5% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $350 million for fiscal 2020, the year ended 31 December 2020, up 8.5% on the year before. Net income was $1 million, down 97.1%, and diluted earnings per share $0.03. The figures are the company's own, from the 10-K it filed with the SEC on 15 March 2021.
Revenue
$350 million
+8.5% on the year
FY2013FY2020
Operating margin
3.1%
-0.0% a year earlier
FY2013FY2020
Net income
$1 million
-97.1% on the year
FY2013FY2020
Diluted EPS
$0.03
-96.9% on the year
FY2013FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
350
322
295
+8.5%
Cost of revenue
207
190
188
+8.4%
Gross profit
143
132
107
+8.7%
Gross margin
41.0%
40.9%
36.3%
Research and development
67.2
68.9
57.6
-2.4%
Operating income
11.0
-0.0
-8.6
Operating margin
3.1%
-0.0%
-2.9%
Interest expense
0.4
0.1
0.2
+214.3%
Pre-tax income
4.6
60.2
-9.9
-92.3%
Income tax
3.5
13.7
-3.3
-74.2%
Effective tax rate
76.3%
22.8%
n/a
Net income
1.4
48.9
-5.7
-97.1%
Net margin
0.4%
15.2%
-1.9%
Diluted EPS
$0.03
$0.98
-$0.12
-96.9%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
57.3
41.8
38.2
+37.1%
Capital expenditure
33.9
41.6
46.8
-18.5%
Free cash flow
23.4
0.2
-8.6
+11,209.7%
Free cash flow margin
6.7%
0.1%
-2.9%
Cash from investing
-36.4
-50.5
-42.2
Cash from financing
-2.2
-3.8
25.0
Depreciation and amortisation
9.0
7.1
6.1
+27.9%
Share-based compensation
20.5
17.3
16.7
+18.5%
Buybacks
24.4
22.3
25.0
+9.6%
Diluted shares, weighted
49m
50m
46m
-1.6%
Shares outstanding at period end
47m
47m
47m
+2.0%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
402
381
332
+5.5%
Non-controlling interest
46.4
46.2
31.9
+0.6%
Debt
45.9
46.3
49.1
-0.9%
Operating lease liabilities
17.5
16.3
n/a
+7.0%
Finance lease liabilities
0.6
n/a
n/a
Other liabilities
119
96.8
100
+22.4%
Total liabilities and equity
631
587
514
+7.5%
Fixed assets
260
234
210
+11.2%
Goodwill
3.9
3.6
4.0
+8.4%
Intangible assets
7.5
8.3
9.1
-10.2%
Investments
13.0
11.7
2.8
+11.2%
Cash and equivalents
92.6
73.7
86.3
+25.7%
Receivables
66.0
45.4
52.2
+45.5%
Inventory
96.8
111
69.3
-12.4%
Other assets
91.3
100.0
79.5
-8.6%
Total assets
631
587
514
+7.5%
10-K for the year ended 31 December 2020, filed 15 March 2021: the filing.